Number Crunch Not Enough Information | GenomeWeb

Lee Babiss, head of preclinical R&D for Hoffman-LaRoche, told an audience at the Genome Tri-Conference in February that between 1996 and 1999, big pharma doubled the number of targets under scrutiny. But the new flood of targets is not accompanied by a flood of data. Each target is much less documented with literature references than in the past, he says.

Percent of targets in the typical pharmaceutical company’s portfolio that are culled from the scientific literature: 90

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.